Keyphrases
Abnormal LFTs
15%
Abnormal Liver Tests
15%
Additional Value
15%
Alirocumab
46%
Cardiovascular Morbidity
46%
Cardiovascular Mortality
46%
Chronic Kidney Disease
92%
Chronic Kidney Disease Risk
15%
Chronic Liver Disease
92%
Clinical Feedback
15%
Comorbid
7%
Diagnostic Laboratory
15%
Digital Health Record
7%
Elevated ALT
7%
Etiology
7%
Evolocumab
46%
Fibrosis
38%
Fibrosis Regression
7%
Health Board
46%
Hepatic Fibrosis
92%
Hepatology
15%
High Cardiovascular Risk
46%
Homozygous Familial Hypercholesterolemia (HoFH)
46%
Hypercholesterolemia
46%
Inclisiran
9%
Increased Mortality
7%
Independent Risk Factors
7%
Intelligent Approach
15%
Intelligent Laboratory
92%
Laboratory Approaches
92%
Laboratory Investigation
30%
Lipid-lowering Therapy
46%
Liver Fibrosis
38%
Liver Function Tests
100%
Living with
23%
Log-binomial Model
7%
Metabolic-associated Fatty Liver Disease (MAFLD)
92%
Mortality Risk
38%
Normal Cholesterol
9%
Novel Algorithm
15%
Primary Care
15%
Primary Care Services
15%
Proprotein Convertase Subtilisin/kexin Type 9 Inhibitors
92%
Real-world Clinical Practice
92%
Real-world Effectiveness
46%
Routine Care
46%
Scotland
69%
Statins
46%
Tayside
23%
Tolerability
92%
Pharmacology, Toxicology and Pharmaceutical Science
Alirocumab
46%
Cardiovascular Mortality
46%
Cardiovascular Risk
46%
Chronic Kidney Failure
92%
Ethanol
12%
Evolocumab
46%
Familial Hypercholesterolemia
46%
Fibrosis
30%
Hydroxymethylglutaryl Coenzyme A Reductase Inhibitor
46%
Hypercholesterolemia
46%
Inclisiran
5%
Kidney Fibrosis
6%
Liver Disease
92%
Liver Fibrosis
92%
Observational Study
6%
Proprotein Convertase 9
92%
Tolerability
92%
Medicine and Dentistry
Alcohol Consumption
6%
Alirocumab
9%
Chronic Kidney Disease
92%
Chronic Liver Disease
92%
Diabetes
6%
Diagnosis
15%
Digital Health
6%
Evolocumab
9%
Fibrosis
36%
Hepatology
15%
Inclisiran
9%
Kidney Function
6%
Liver Fibrosis
92%
Liver Function
98%
Liver Function Test
15%
Metabolic Dysfunction-Associated Steatotic Liver Disease
92%
Metabolic Liver Disease
9%
Observational Study
6%
Primary Health Care
30%
Proportional Hazards Model
6%